Sarepta Therapeutics
SRPT
414 hedge funds and large institutions have $10.8B invested in Sarepta Therapeutics in 2024 Q1 according to their latest regulatory filings, with 77 funds opening new positions, 145 increasing their positions, 122 reducing their positions, and 55 closing their positions.
228% more call options, than puts
Call options by funds: $649M | Put options by funds: $198M
114% more funds holding in top 10
Funds holding in top 10: 7 → 15 (+8)
40% more first-time investments, than exits
New positions opened: 77 | Existing positions closed: 55
34% more capital invested
Capital invested by funds: $8.05B → $10.8B (+$2.73B)
19% more repeat investments, than reductions
Existing positions increased: 145 | Existing positions reduced: 122
5% more funds holding
Funds holding: 395 → 414 (+19)
0.4% less ownership
Funds ownership: 89.11% → 88.71% (-0.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$152M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$133M |
| 3 |
PBA
Paradigm Biocapital Advisors
New York
|
+$132M |
| 4 |
JP Morgan Chase
New York
|
+$64.4M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$57.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$229M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$108M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$68.5M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$55.7M |
| 5 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$48.2M |
SRPT Hedge Fund Activity: Q1 2024 in Review
414 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q1 2024, worth a combined $10.8B — up 34% from $8.05B a quarter earlier.
Buyers outnumbered sellers: 77 funds opened new SRPT positions and 55 closed out — a net gain of 22 holders — while 145 added to existing stakes and 122 trimmed.
The largest buyer was Farallon Capital Management, adding an estimated $152M. The largest seller was Morgan Stanley, cutting an estimated $229M.
- 414 institutional investors held Sarepta Therapeutics (SRPT) as of Q1 2024, up from 395 in Q4 2023.
- Funds reported $10.8B of Sarepta Therapeutics stock for Q1 2024, up 34% quarter-over-quarter.
- 77 funds opened new Sarepta Therapeutics positions in Q1 2024 and 55 closed out, a net change of +22 holders.
- The largest Sarepta Therapeutics buyer in Q1 2024 was Farallon Capital Management, an estimated $152M added.
- The largest Sarepta Therapeutics seller in Q1 2024 was Morgan Stanley, an estimated $229M sold.
Based on aggregated 13F filings for Q1 2024.